UTILISATION DE VIRUS ONCOLYTIQUES, SEULS OU EN COMBINAISON AVEC UN INHIBITEUR DE POINT DE CONTROLE IMMUNITAIRE, POUR LE TRAITEMENT DU CANCER

• 收藏
• 分享

专利权人:

AMGEN INC.

发明人:

BELTRAN, PEDRO J.,BEERS, COURTNEY,COOKE, KEEGAN

申请号：

CA3056392

公开号：

CA3056392A1

申请日:

2018.03.14

申请国别(地区):

CA

年份:

2018

代理人:

摘要：

The present invention relates to the use of oncolytic viruses (e.g., talimogene laherparepvec), either alone or in combination with immune checkpoint inhibitors (e.g., anti-CTLA-4, anti-PD-1, and anti-PD-L1 compounds such an antibodies) for the treatment of various types of cancer. In addition, the present invention relates to compositions and kits relating to such uses of oncolytic viruses, either alone or in combination with immune checkpoint inhibitors.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/